PT - JOURNAL ARTICLE AU - Sultan, Iyad AU - Tbakhi, Abdelghani AU - Abuatta, Osama AU - Mubarak, Sawsan AU - Alsmadi, Osama AU - Edilbi, Adib AU - Al-Ani, Ruba AU - Makhlouf, Manar AU - Hajir, Rawan AU - Khreisat, Omar AU - Al-Ruzzieh, Majeda A. AU - Abdelrazeq, Hikmat AU - Mansour, Asem TI - Distinct Vaccine Efficacy Rates Among Health Care Workers During a COVID-19 Outbreak in Jordan AID - 10.1101/2022.01.15.22269356 DP - 2022 Jan 01 TA - medRxiv PG - 2022.01.15.22269356 4099 - http://medrxiv.org/content/early/2022/01/16/2022.01.15.22269356.short 4100 - http://medrxiv.org/content/early/2022/01/16/2022.01.15.22269356.full AB - BACKGROUND We aimed to assess the efficacy of 3 COVID-19 vaccines in a population of health care workers at a tertiary cancer center in Amman, Jordan.METHODS We evaluated the records of 2855 employees who were fully vaccinated with 1 of 3 different vaccines and those of 140 employees who were not vaccinated. We measured the number of SARS-CoV-2 infections that occurred at least 14 days after the second vaccine dose.RESULTS The 100-day cumulative incidence of PCR-confirmed SARS-CoV-2 infections was 19.3% ± 3.3% for unvaccinated employees and 1.7% ± 0.27% for fully vaccinated employees. The 100-day cumulative infection rates were 0.7% ± 0.22% in BNT162b2 vaccine recipients (n = 1714), 3.6% ± 0.77% in BBIBP-CorV recipients (n = 680), and 2.3% ± 0.73% in ChAdOx1 recipients (n = 456). We used Cox regression analyses to compare the risks of SARS-CoV-2 infection among the different vaccine recipient groups and found a significantly higher infection risk in BBIBP-CorV (hazard ratio [HR] = 2.9 ± 0.31) and ChAdOx1 recipients (HR = 3.0 ± 0.41) compared to BNT162b2 recipients (P = .00039 and .0074, respectively). Vaccinated employees who had no previously confirmed SARS-CoV-2 infections were at a markedly higher risk for breakthrough infections than those who experienced prior infections (HR = 5.7 ± 0.73, P = .0178).CONCLUSIONS Our study offers a real-world example of differential vaccine efficacy among a high-risk population during a national outbreak. We also show the important synergism between a previous SARS-CoV-2 infection and vaccination.Funding NoneCompeting Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:IRB of King Hussein Cancer Center gave ethical approval for this work (KHCC-IRB#21KHCC110)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors